Exvivo Experiments of Human Ovarian Cancer Ascites-Derived Exosomes Presented by Dendritic Cells Derived from Umbilical Cord Blood for Immunotherapy Treatment by Li, Qi-Ling et al.
Clinical Medicine: Oncology 2008:2 461–467 461
ORIGINAL RESEARCH
Correspondence: Professor, Xiao-Yan Xin, Department of Gynecology and Obstetrics, Xijing Hospital, 
Fourth Military Medical University, Xi’an 710032, Shannxi Province, P.R.China. Tel: +86-029-83375387; 
Email: gynobs@fmmu.edu.cn
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Exvivo Experiments of Human Ovarian Cancer 
Ascites-Derived Exosomes Presented by Dendritic Cells Derived 
from Umbilical Cord Blood for Immunotherapy Treatment
Qi-Ling Li
1, Ning Bu
2, Yue-Cheng Yu
1, Wei Hua
1 and Xiao-Yan Xin
1,3
1Department of Gynecology and Obstetrics, Xijing Hospital, Fourth Military Medical University, Xi’an 
710033, Shannxi Province, P.R. China. 
2Department of Neurology, Second Affiliated Hospital, Xi’an 
Jiaotong University, Xi’an 710004, Shannxi Province, P.R. China.
Abstract
Objectives: Exosomes, a type of membrane vesicles, released from tumor cells have been shown to be capable of transferring 
tumor antigens to dendritic cells and activating speciﬁ  c cytotoxic T-lymphocytes. Recent work has demonstrated the pres-
ence of high numbers of exosomes in malignant effusions. Umbilical cord blood (UCB) is a rich source of hematopoietic 
stem cells and from which a signiﬁ  cant number of dendritic cells can be produced. We hypothesized that the exosomes 
released from metastatic ovarian carcinoma were able to present tumor speciﬁ  c antigen to dendritic cells derived from 
unrelated umbilical cord blood, then could stimulate resting T cells to differentiate and induce effective cytotoxicity.
Study design: Exosomes were isolated by ultracentrifugation of malignant ascites from ovarian cancer patients (n = 10). 
Puriﬁ  ed exosomes were further characterized by Western blot analyses and immunoelectronic microscopy. Dendritic cells 
were collected from unrelated umbilical cord blood and cultured in the presence of GM-CSF, IL-4 and TNF-α. Resting 
T cells were mixed with dentritic cells previously primed with exosomes and the cytotoxicity were measured by MTT 
method. T cells were activated by DCs presented with exosomes.
Results: 1) the exosomes isolated from the ascites were membrane vesicles of about 30–90nm in diameter; 2) the exosomes 
expressed MHC class I molecules, HSP70, HSP90, Her2/Neu, and Mart1; and 3)umbilical cord blood-derived DCs previ-
ously exosome-primed stimulated resting T cells to differentiate and produce effective cytotoxicity.
Conclusions: These results suggested that tumor-speciﬁ  c antigens present on exosomes can be presented by DCs derived 
from unrelated umbilical cord blood to induce tumor speciﬁ  c cytotoxicity and this may represent as a novel immunotherapy 
for ovarian cancer.
Keywords: exosome, dendritic cells, umbilical cord blood, ovarian cancer, immunotherapy
Introduction
Exosomes are small membrane vesicles secreted into the extracellular compartment by exocytosis. 
Tumor cells secrete exosome-like vesicles. These subcellular membrane vesicles from endosomal 
origin are secreted upon fusion of multi-vesicular bodies with the plasma membrane [1, 2]. As a con-
sequence, exosomes have a “cellular” membrane oriented with a limited variety of proteins derived 
from the cytosol, endocytic compartment membranes, and plasma membranes [3]. They are 30 to 
90 nm in diameter, and may be involved in the communication between cells. The presence of proteins 
potentially involved in cell targeting and tumor antigen transportation in exosomes prompted us to 
hypothesize that tumor cell-derived exosomes could be antigen delivery systems allowing transfer 
tumor antigen from tumor cells to APC. Wolfers [4] demonstrated that tumor-derived exosomes in the 
supernatants of a tumor cell line contained and were capable of transferring tumor antigens to the DCs. 
Recent work suggested that tumor derived-exosomes are immunogenic [5] and exosomes may be a 
novel source of tumor-speciﬁ  c antigens which may be used for T-cell cross priming and be relevant 
for immuno-interventions.462
Li et al
Clinical Medicine: Oncology 2008:2   
Unrelated UCB offers many practical advan-
tages as an alternative source of stem cells, includ-
ing: 1) absence of risk for mothers and donors; 
2) relative ease of procedure and greater availabil-
ity comparing to unrelated bone marrow graft [6]; 
3) the ability to store fully tested and HLA-typed 
cord blood in the frozen state, and availability for 
immediate use to transplant centers [7]; 4) a 
reduced likelihood of transmitting infections, 
particularly cytomegalovirus; 5) less stringent 
criteria for HLA matching for donor-recipient 
selection; 6) the absence of donor attrition and 7) 
a potentially reduced risk of GVHD [8].
Exosomes derived from tumor cell lines trans-
fer shared tumor antigens to DCs and, thus stimu-
late T cells in an MHC class I dependent way, and 
provide cross-protection against syngeneic and 
allogeneic tumors in mice [9]. In this study, we 
hypothesized that the exosomes derived from 
ascites of the patients with ovarian cancer were 
able to present tumor speciﬁ  c antigen to unrelated 
umbilical cord blood-derived dendritic cells, to 
stimulate T cells to differentiate, and to induce 
effective cytotoxicity.
Materials and Methods
Patients
Ascites samples were collected from the inpatients 
in the OB and GY department of Xijing Hospital 
in Fourth Military Medical University. We included 
patients who presented with ovarian cancer associ-
ated with ascites and had tumor cells in the bio-
logical ﬂ  uid. All patients have given their consents. 
Ascites were removed either at the ﬁ  rst debulking 
operation or examination. We excluded patients 
who had received chemotherapy within 4 weeks 
before the removal of their ascites, had a concen-
tration of protein in the exudates that was below 
30g/L, or had haemorrhage associated with carci-
nomatosis.
Preparation of umbilical cord blood 
samples
UCB samples were obtained from the umbilical 
cord of full-term babies from non-diabetic non-in-
fectious disease mother according to conditions 
established by the OB&GY department of Xijing 
Hospital in Fourth Military Medical University. 
The cells were processed within 24 hours after 
collection.
Isolation of exosomes
Ascites samples were centrifuged at 300 g to 
remove the ﬂ  oating cells and the supernatant were 
collected and subjected to subsequent centrifuga-
tion steps (at 800 g for 30 min, followed by 10,000 
g for 30 min, and then 100,000 g for 1 h). The pel-
let was recovered and resuspended in a phos-
phate-buffered saline (PBS) solution and then 
subjected to differential centrifugation at 90,000 g 
for 1.25 h on a gradient column. The exosomes 
contained in the 30% sucrose/D2O cushion were 
recovered, resupended in phosphate-buffered 
saline, and concentrated by ultracentrifugation at 
100, 000g for 1 h, as previously described [5]. The 
pellet was then resupended in saline and stored 
at –80 °C. The ﬁ  nal quantiﬁ  cation of exosomal 
proteins was measured by a CBA kit according to 
the manufacturer’s recommendations [10].
Electron microscopy
Exosomes obtained after differential ultracentrifu-
gation were ﬁ  xed in 30µL Phosphorus tungstic acid 
(20g/L) and negatively stained for about 1 min. 
The stained exosomes were then examined under 
electronic microscopy. When indicated, we per-
formed single immunogold labeling before the 
contrasting step using a monoclonal antibody to 
human MHC class I molecules (Soldano Ferrone, 
USA, -clone 1A6); to Hsc70(Stressgen, Canada, -clone 
N27F3); to Hsp90 (Shanghai Universal Biotech 
Company, -clone 1A6); to MHC class molecules 
(Novocastra, UK, -clone 3B5); to Mart1(Novocastra, 
UK, -clone A103), or Her2/Neu (-clone ncb11). 
The antibodies were then visualized with protein 
A previously coupled to 5 nm gold particles 
(Boster, China).
Western blot analysis
Exosomal or cell-lysate protein were extracted as 
described previously[4]. Exosomal or cell-lysate 
protein then were analyzed by western blotting 
using a monoclonal antibody to human. We ana-
lyzed them by Western blotting with a monoclonal 
antibody to human MHC class I molecules; to 
Hsc70; to Hsp90; to MHC class molecules; to 
Mart1/Melan A, or Her2/Neu. The signal was then 
detected using a horseradish peroxidase conjugated 463
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anti-mouse antibody and chemiluminescence 
detection kit.
Preparing DCs from human umbilical 
cord blood
Fresh UCB samples were diluted 1:4 in PBS. 
After centrifugation in Ficoll-Hypaque (Tianjin 
Hematology Institute, China) at 400 r/min for 35 
min, mononuclear cells were collected from the 
interface and washed twice in PBS by centrifuga-
tion at 200 r/min for 10 min. The mononuclear 
cells were then labeled with a CD34+ progeni-
tor cell isolation kit (Miltenyi Biotec, Germany) 
and the CD34+ hematopoietic stem cells were 
obtained Mini magnetic cell sorting (Mini 
MACS, Miltenyi Biotec, Germany) according to 
the protocol. DCs were induced from cord blood 
CD34+ hematopoietic stem cells as previously 
described [11]. The differentiation of DCs was 
examined under a phase contrast microscope. On 
the 10th day, the tumor-derived exosomes were 
added to the DC culture and on the 14th day, the 
exosome-primed DCs were collected as effector 
cells (a).
DCs surface phenotyping by ﬂ  ow 
cytometry
The following mAbs were used to characterize 
DCs surface phenotypes: PE-conjugated anti-CD11c 
(BD PharMingen, America); FITC-conjugated 
anti-CD80 (BD PharMingen, America); PE-con-
jugated anti-CD86 (BD PharMingen, America), 
FITC-conjugated anti-HLA-DR(BD PharMingen, 
America). The harvested exosome-primed DCs 
were washed, resuspended in PBS supplemented 
with 1% BSA and 0.01% NaN3, and incubated with 
the mAbs for 30 minutes on ice. The cells were 
washed twice in PBS and 1 × 10
4 of those labeled 
cells were subjected to FACS ﬂ  ow cytometric 
analysis using a Cellquest software.
Isolation of epithelial ovarian cancer 
cells and T cells from ascites
Ovarian cancer cells were isolated from freshly 
collected malignant ascites as described previously 
[12]. T cells were isolated from the ascites as pre-
viously described [13]. T cells (at a density of 
2 × 10
5 cells/well) were cultured with effector cells 
(a) (at a density of 1 × 10
4 cells/well) in 96-well 
culture plate for 48 h, as effector cells(b).
Assessment of cytotoxicity by MTT 
assay
The ovarian cancer cells were seeded at a concen-
tration of 5 × 10
4 cells/ml in a 96-well culture 
plate. Autologous effector cells(b) were added 
according to variable concentration. Ovarian can-
cer cells from ascites were used as blank control 
cells. After 48 hrs of culture, 3-[4,5-dimethylthia
zol-2-yl]- 2,5- diphenyltetrazolium bromide 
(MTT) was added at a concentration of 0.5 mg/ml 
and incubated at 37 °C in CO2 incubator for an 
additional 24 hrs. Viable DCs generated insoluble 
crystal, but dead DCs were ﬂ  oating or loosely 
attached on the surface of culture plates. 10% SDS 
solution containing 0.01 N HCl was directly added 
into wells (100 L/well) to dissolve the insoluble 
crystal generated by DCs and to avoid the poten-
tial loss of samples. After 24 hrs, the absorbance 
of each sample was measured at 490 nm, using a 
microplate reader and the absorbance of each 
sample, 570 nm was used as reference.
Statistical analysis
Data were analyzed with SPSS10.0 statistical 
software. Two-sided P < 0.05 was considered sta-
tistically signiﬁ  cant.
Results
Sucrose gradient ultracentrifugation
After overnight centrifugation of the ﬂ  uorescent-
labeled ascites, various yellow-white layers 
appeared in the sucrose gradient. In all samples, 
electronic microscopic analysis of these ﬂ  uores-
cent fractions conﬁ  rmed the presence of round 
homogeneous membrane vesicles which fulﬁ  lled 
the deﬁ  nition of exosome. Some variations in 
both shape and diameter of exosomes were 
observed among samples. The concentration of 
exosomes in ﬂ  uorescent fractions varied even 
between samples from the same patient and the 
exosomes were occasionally mixed with other 
types of cell membrane fragments. When anti-
bodies of MHC class I molecules, Her2/Neu and 
Mart1 were used to label the exosomes, gold 
particles were seen by immunity electronic 
microscopy (Fig. 1), whereas the sample labeled 
with antibodies to HSP70 or Hsp90 did not show 
any gold particles.464
Li et al
Clinical Medicine: Oncology 2008:2   
Western blot analysis
Western blot analysis of the exosomes isolated 
from patients (n = 10) showed the presence of 
MHC class I molecules, HSP70, Hsp90, Her2/Neu, 
and Mart1(Fig. 2).
Generation of DCs from cord blood 
CD34+ cells
CD34+ isolated cells from cord blood were round 
and regular with a diameter of approximately 
7–8 µm. Upon stimulation with rhGM-CSF, IL-4, 
and rhTNF-α, the cell number increased and cell 
clone formed. The cells also produced cytoplasmic 
projections. During the late period of culture, DCs 
shed from the clones into the medium. On day 14, 
the total number of cells increased by about 
20-fold.
DCs surface phenotyping by ﬂ  ow 
cytometry
The expression of CD11c, HLA-DR, CD80 and 
CD86 was gradually increased in DCs stimulated 
with rhGM-CAF, rhIL-4, and TNF-α. On day 3, 
approximately 13.2%, 16.3%, 20.6%, and 15.1% 
of DCs expressed CD11c, HLA-DR, CD80, and 
CD86, respectively and these numbers increased 
to 76.1%, 68.0%, 56.3% and 54.8% on day 12 
(Fig. 3).
c  a b
Figure 1. Immunoelectron micrograph of exosomes labeled with antibodies to (a) MHC class I molecules, (b) Her2/Neu, and (c) Mart1. Black 
dot indicated the presence of the 5 nm gold particles.
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Figure 2. The presence of MHC class I molecules, HSP70, HSP90, Her2/Neu and Mart1 was conﬁ  rmed by Western blotting in the exosome 
containing fraction isolated from malignant pleural ﬂ  uid from patients with ovarian cancer. (tumor: lysated cells of ovarian cancer; ascites: 
ascites from the patients with ovarian cancer; exo-as: exosome derived from ascites of the patients with ovarian cancer).465
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Cytotoxicity of DC-primed 
lymphocytes in vitro
Lymphocytes were primed by exosomes pulsed-DCs 
at responder-to-stimulator ratio of 10:1, 20:1and 
30:1 respectively. As shown in Table 1 and Table 2, 
the neutral red absorbance value(A value) of viable 
tumor cells at ratio of 30:1 in exo-DC-T group and 
exo-T group was signiﬁ  cantly lower than that in 
DC-T and T groups (P < 0.01). There was no 
signiﬁ  cant difference in A value between DC-T 
group and T group (P > 0.05). According to A value, 
the cytotoxicity of exo-T group or exo-DC-T group 
was 40.09% or 53.92% respectively, while the 
cytotoxicity without exosomes was 13.87% and 
19.75%.
Dicussion
Ideally, immunotherapeutic strategies aimed at 
immunizing the host should be able to elicit 
T-cell–mediated immune responses against a broad 
repertoire of tumor speciﬁ  c antigens. While mature 
DCs appear to be the most potent natural adjuvants, 
optimal protocols leading to efﬁ  cient DC uptaking, 
processing, and cross-presentation in association 
with MHC class I molecules, are still lack. Several 
approaches involving the use of whole tumor RNA, 
tumor lysates, apoptotic or necrotic debris and 
fusion are currently under investigation [4]. Exo-
somes are released in vitro by many types of cells 
including tumor cell lines [4] and antigen present-
ing cells [1, 14]. These membrane vesicles have a 
different spectrum of proteins compared with 
plasma membranes and are enriched in molecules 
involved in antigen presentation and proteins 
involved potentially in cell targeting. Recent work 
suggested that tumor-derived exosomes contain a 
spectrum of tumor speciﬁ  c antigens and play a role 
in immunotherapy directed towards malignant 
tumors [5]. When exosomes are combined with 
source DCs, the exosomes probably interact 
directly with cognate receptors on the T cells via 
costimulatory molecules, and therefore induce 
more efﬁ  cient T-cell activation [15]. Plasmacytoma 
cells were shown to release exosomes in vitro, and 
vaccination with a single dose (5 µg) of exosomal 
protein protected 80% of mice against challenge 
with wild-type tumors. The protection was likely 
CD11c
HLA-DR
CD80
CD86
Day 3 Day12
Figure 3. Flow cytometric analysis of phenotypic changes in DCs upon in-vitro stimulations with rhGM-CSF, IL-4 and TNF-α on day 3 and 
day 12.466
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Table 2. Neutral red absorbance value (A value) of 
ovarian cancer cells from ascites and cytotoxicity of 
effector cells in different groups at responder-
to-stimulator ratio of 30:1(mean ± SD).
Group A  Cytotoxicity
   (%)
Control 0.1369  ± 0.0145 
T 0.1087  ± 0.0256
a 13.87
DC-T 0.0945  ± 0.0345
a 19.75
exo-T   0.0528  ± 0.0145
b,c 40.09
exo-DC-T   0.0370  ± 0.0136
b,d,e 53.92
aP < 0.05 vs control group, 
bP < 0.01 vs control group, 
cP < 0.01 vs 
T group, 
dP < 0.01 vs DC-T group 
eP < 0.05 vs exo-T group.
to be related to the immune system since vaccinated 
mice generated speciﬁ  c cytotoxic T lymphocytes, 
the effects were not seen in SCID mice, and immu-
nity was tumor-speciﬁ  c [16].
Exosomes present in malignant ascites may 
have various cellular origins. Malignant ascites is 
accompanied by a strong inﬂ  ammatory response 
involving both cellular and humoral immunity. The 
most abundant cells in the ascites of our 10 patients 
were lymphocytes and tumor cells. B-lymphocytes, 
T-lymphocytes, and antigen-presenting cells such 
as dendritic cells are important participants of the 
anti-tumoral immune response, and are all known 
to produce exosomes [1, 17]. Moreover, tumor cells 
are also able to produce exosomes [3, 4, 18, 19].
Ovarian cancer cells are also able to produce 
exosomes [20, 21]. In this study, the exosomes 
isolated from body ﬂ  uids expressed MHC class I 
molecules, HSP70, HSP90, Her2/Neu and Mart1, 
similar to tumor cells, when examined with west-
ern blotting and electronic microscopy. Our results 
suggest that carcinomatous ascites contain a com-
bination of exosomes of ovarian cancer-origins. 
We further determined the MHC class concentra-
tion on the exosomes. Our results demonstrated 
that the exosomes isolated from the carcinomatous 
ascites contained MHC molecules (class I but not 
class II) and heat short proteins. Our results were 
in line with previous reports that these molecules 
were commonly identiﬁ  ed in exosomes originating 
from various cells such as B cells, T cells, dendritic 
cells, and tumor cells [4,14,22] and recent work 
by André and colleagues showing the presence of 
MHC class I molecules in malignant ascites-de-
rived exosomes by electron microscopic immu-
nostaining and Western blotting [18]. Functions of 
these proteins in exosomes have been related to 
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their capacity to transfer antigens to antigen pre-
senting cells and to induce a speciﬁ  c immune 
response. These results prompted us to hypothesize 
that exosomes derived from ascites could be 
administered as a novel source of speciﬁ  c antigens 
in the development of immunotherapy.
To test our hypothesis that exosomes derived 
from ascites could be administered as a novel source 
of speciﬁ  c antigens in the development of immu-
notherapy, we performed the following experiments 
to determine if the exosomes with tumor antigens 
and costimulatory molecules isolated from ascites 
of patients with ovarian cancer could directly acti-
vate neonatal T cells and produce cytotoxicity. Our 
results showed the cytotoxicity of Exo-DC-T group 
was higher than that of Exo-T group and the DCs 
isolated from unrelated UCB were more efﬁ  cient 
of activating T cells and producing more cytotoxic-
ity when these DCs were primed with malignant 
ascites-derived exosomes. In conclusion, cancerous 
ascites contains exosomes from tumor cell origin. 
The proteomic analysis of ascites-derived exosomes 
in this study demonstrated that these exosomes 
expressing a variety of proteins including MHC 
class I molecules, HSP70, Hsp90, Her2/Neu, and 
Mart1 which are potentially involved in antigen 
presentation and activation of T-cell dependent 
immunity. Our current study also demonstrated that 
large number of DCs could be isolated from unre-
lated UCB and used as APCs to activate resting T 
cells and lead to effective cytotoxicity in the pres-
ence of malignant ascites-derived exosomes.
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